Sarepta Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sarepta Therapeutics sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Sarepta Therapeutics: 33 sponsored US clinical trials, 1 recruiting.
Sarepta Therapeutics sponsors 33 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 19 completed. 7 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Muscular Dystrophy, Duchenne, with 3 trials.
Top-decile sponsor footprint
Sarepta Therapeutics ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT04626674
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
NCT06246513
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
NCT06747273
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
NCT06597656
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
NCT05906251
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05096221
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
NCT04004065
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
NCT03675126
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
NCT03769116
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
NCT03652259
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
NCT03532542
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
NCT03375255
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT03375164
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
NCT02500381
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
NCT02710500
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
NCT02530905
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
NCT02420379
Phase I/II Study of SRP-4053 in DMD Patients
NCT02310906
Study of Eteplirsen in DMD Patients
NCT02255552
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
NCT02286947
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
NCT01566877
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
NCT01540409
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
NCT01396239
Safety Study of Single Administration Intravenous Treatment for Influenza
NCT01375985
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
NCT01353040
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
NCT01353027
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
NCT00387283
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
NCT00381433
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
NCT00343148
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 5 |
| Phase 3 | 7 |
Therapeutic Areas
What is open in the Sarepta Therapeutics pipeline
1 recruiting of 33 indexed (3% open); 19 completed (58%).
Phase mix: 7 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Muscular Dystrophy, Duchenne (3 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sarepta Therapeutics: open-pipeline peers nationwide
Peers matched on 33 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sarepta Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors near 3% open enrollment (± trial volume)
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
- Kyowa Kirin · 3% recruiting · 34 trials
Related
What to do with this Sarepta Therapeutics page
33 registered trials is a research-attention snapshot, not an endorsement of Sarepta Therapeutics or any single study.
- 1 of Sarepta Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Muscular Dystrophy, Duchenne is the condition Sarepta Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Muscular Dystrophy, Duchenne trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sarepta Therapeutics pipeline card: 33 registered trials from official public datasets.Report a data error.